Merck projects billions in sales of COVID drug

Merck & Co.’s closely watched COVID-19 antiviral molnupiravir could bring in as much as $7 billion in global sales through 2022, according to the drugmaker.

Related Keywords

United States ,Caroline Litchfield ,Merck Co ,Chief Financial Officer Caroline Litchfield ,Wall Street ,Nation And World ,Op Stories ,